Spots Global Cancer Trial Database for Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma
Official Title: A Phase Ib/II, Open-label, Multicenter Study of Oral HDM201 in Combination With Oral LEE011 in Adult Patients With Liposarcoma
Study ID: NCT02343172
Conditions
Study Description
Brief Summary: To determine the MTD/RP2D of the HDM201 and LEE011 combination and evaluate whether the combination is safe and has beneficial effects in patients with liposarcoma.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Novartis Investigative Site, Toronto, Ontario, Canada
Novartis Investigative Site, Bordeaux, , France
Novartis Investigative Site, Lyon Cedex, , France
Novartis Investigative Site, Essen, , Germany
Novartis Investigative Site, Ulm, , Germany
Novartis Investigative Site, Singapore, , Singapore
Novartis Investigative Site, Barcelona, Catalunya, Spain
Novartis Investigative Site, Madrid, , Spain
Novartis Investigative Site, Taipei, , Taiwan
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
